Intravascular Lithotripsy Market Size, Share, & Trends Analysis | Global | 2025-2032 | Includes: Coronary and Peripheral Modalities

Global Intravascular Lithotripsy Market Report

The global intravascular lithotripsy market was valued at just over $1.1 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 19.5% to reach over $3.8 billion by 2032.

The global intravascular lithotripsy, or IVL, market includes catheter-based systems used for calcium modification in both coronary and peripheral vascular interventions. This report analyzes the combined IVL market across North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa, providing market value, unit volume and average selling price analysis for each region, with forecasts extending through 2032. The structure and flow of this report description follow the same format used in the attached example document, adapted to the IVL category and its specific competitive and clinical dynamics .

This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with forecasts through 2032 and historical data to 2022. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The market is further segmented by modality into coronary and peripheral IVL.

• IVL has become one of the fastest-growing categories in vascular intervention because it addresses one of the most difficult procedural challenges in both coronary and peripheral care: severe calcification. Calcified lesions can limit device deliverability, reduce balloon expansion, complicate stent placement and worsen final procedural outcomes. IVL gives physicians a catheter-based way to modify calcium while preserving vessel integrity, which makes it highly relevant in complex cases.

Growth is being supported by expanding clinical evidence, broader physician familiarity and a widening set of use cases. In peripheral intervention, IVL adoption is accelerating especially quickly because of its expanding role in large-bore vascular access preparation for procedures such as transcatheter aortic valve replacement and endovascular aortic aneurysm repair. In coronary intervention, it continues to gain traction as a safer and more controlled calcium-modification tool during complex PCI. Together, these trends are driving strong global market expansion.

Market Overview

The global intravascular lithotripsy market includes balloon-based catheter systems that deliver pulsatile sonic pressure waves to fracture vascular calcium before or during balloon expansion. These devices are used in both coronary and peripheral procedures to improve vessel compliance and support better lesion preparation before definitive therapy.

IVL is gaining importance because calcified disease is a growing problem across modern vascular care. Aging populations and the rising prevalence of diabetes, hypertension and chronic kidney disease are increasing the number of patients with heavily calcified coronary and peripheral lesions. These lesions are often difficult to treat with conventional balloon angioplasty alone and can complicate the use of stents and other devices. As a result, the need for dedicated calcium-modification technologies continues to rise.

One of the most important advantages of IVL is that it modifies calcium while preserving vessel integrity more effectively than many alternative tools in selected cases. Rather than relying on aggressive cutting, drilling or high-pressure expansion alone, IVL uses localized energy to disrupt calcium and improve vessel compliance. This supports safer device delivery, more predictable expansion and potentially lower procedural trauma in appropriately selected lesions.

Even so, IVL remains a premium technology. High device cost, reimbursement variability and competition from established alternatives still shape usage patterns across global markets. This means the category is growing quickly, but adoption remains most concentrated in procedures where the clinical need is strongest and the procedural value is easiest to justify.

Market Drivers

Positive Clinical Outcomes

One of the strongest drivers of the global IVL market is the growing body of positive clinical evidence supporting the technology. Across both coronary and peripheral applications, randomized trials and real-world registries have shown high procedural success rates, effective calcium modification and low complication profiles. These findings are important because physician adoption in a premium device category depends heavily on trust in safety and performance.

As more mid-term and long-term data become available, physician confidence continues to improve. Strong outcomes do not just support use in existing cases. They also encourage broader adoption in hospitals and labs that may have initially been cautious. This evidence base is therefore central to IVL's continued growth.

Prevalence of Coronary Artery Disease

The increasing burden of calcified coronary artery disease is another major market driver. Aging populations and the growing prevalence of diabetes, hypertension and chronic kidney disease are all contributing to more complex lesion profiles. These patients are more likely to present with severe calcium, which increases the need for dedicated preparation tools before stenting or other intervention.

This same demographic shift also affects peripheral vascular care, so the driver supports both sides of the market. In practice, this means that rising disease complexity is not just increasing procedure volume. It is increasing the need for more advanced tools within those procedures, which directly benefits IVL.

Expanded Clinical Applications

IVL growth is also supported by broader clinical applicability. As indications have expanded across coronary, peripheral and below-the-knee anatomy, the technology has become relevant in a wider range of procedures. This matters because broader applicability increases physician familiarity and gives hospitals more reasons to support adoption.

Expanded use also speeds up evidence generation. As IVL is used in more lesion types and more procedural settings, clinicians gain a better understanding of where it works best. This increases confidence, supports best-practice development and helps identify additional future applications. In a market growing this quickly, that cycle of use, evidence and adoption is especially important.

Market Limiters

High Cost per Procedure

The most significant limiter in the global IVL market is the high cost per procedure. IVL balloons are priced well above conventional angioplasty balloons and can also exceed the cost of some atherectomy devices. In cost-sensitive healthcare systems, this price premium can limit use to the most difficult or highest-risk lesions.

This does not eliminate adoption, but it creates selectivity. Physicians and hospitals often reserve IVL for cases where other tools are less suitable or where the expected procedural benefit is clear. That means market penetration, while growing quickly, is still shaped heavily by procedure economics.

Budget and Reimbursement Constraints

Budget and reimbursement constraints also limit broader uptake. In many regions outside the United States, reimbursement adoption is slower and procurement controls are tighter. Even when physicians want to use IVL, hospital budgets or public purchasing rules can reduce routine access.

This creates variability in near-term revenue growth across geographies. Some regions can adopt the technology faster because reimbursement and private purchasing are more favorable. Others move more slowly because budget pressure makes premium device adoption harder to justify. As a result, the market's long-term outlook is strong, but regional growth rates can differ significantly.

Competition from Established Technologies

IVL also competes with well-established calcium-modification alternatives. Rotational atherectomy, orbital atherectomy and specialty balloons all remain important tools in lesion preparation. Many clinicians are deeply experienced with these technologies and may prefer them in less complex cases or where IVL reimbursement is limited.

This is especially relevant because physician habit remains powerful in interventional care. Even a clinically attractive technology must compete against existing tools that are already embedded in practice. For IVL to keep gaining share, it must continue proving that its benefits justify the premium in a growing range of use cases.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support commercial planning, competitive benchmarking and strategic positioning by combining forecast modeling with practical procedural and market context.

Markets Covered and Segmentation

• The report covers the Global Intravascular Lithotripsy Market, further segmented by modality into:

Coronary IVL Market

This segment includes IVL systems used during interventional cardiology procedures to modify severe coronary calcification and improve lesion preparation before stenting or related treatment.

Peripheral IVL Market

This segment includes IVL systems used in peripheral vascular intervention, including lesion preparation and access-enabling applications such as support for TAVR and EVAR access.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the two major clinical use settings that define the global IVL market today.

Competitive Analysis

Johnson & Johnson, through Shockwave Medical, is the undisputed global leader in IVL. In May 2024, Johnson & Johnson completed its acquisition of Shockwave Medical, bringing the only broadly scaled IVL platform for both peripheral vascular and coronary indications fully into the Johnson & Johnson MedTech portfolio. This gives the company unmatched leadership in clinical evidence, regulatory breadth and worldwide commercialization.

Shockwave established the category in the peripheral market with the Lithoplasty System and Peripheral Lithoplasty Balloon Dilation Catheter, first cleared by the FDA in 2016. The company then expanded its leadership through a strong clinical program that included the DISRUPT PAD series and dedicated below-the-knee studies such as DISRUPT BTK and BTK II. In interventional cardiology, Shockwave strengthened its position through the launch of the Shockwave C2 Coronary IVL Catheter, which gave physicians a more controlled option for modifying severe coronary calcification during complex PCI. As the only IVL supplier with significant penetration in both the U.S. and Europe, Shockwave has effectively defined the clinical and economic benchmark for the market.

Johnson & Johnson has also supported long-term global expansion through structured market-access strategies. Its partnership with Genesis MedTech is an example of how the company is preparing for broader participation in China through distribution support and localized manufacturing. With Johnson & Johnson's commercial scale, infrastructure and R&D resources behind it, the Shockwave franchise is expected to remain dominant as IVL adoption expands globally.

MicroPort is an emerging competitor, but its relevance remains concentrated primarily in China. In early 2025, the company received approval in China for its TomaHawk Integrated Coronary IVL System, designed to treat moderate to severe coronary artery calcification. The device includes a proprietary electrode design intended to maintain deliverability while supporting lithotripsy pulse delivery and real-time pressure monitoring.

MicroPort's significance remains mainly regional. The company does not yet approach Johnson & Johnson in clinical depth or international scale, but its domestic manufacturing and established presence in China could allow it to compete effectively in local tenders and hospital purchasing processes. That may create localized pricing pressure and support adoption in China without materially changing global market leadership. Outside China, expansion remains very early. Limited clinical use in Hong Kong and the Philippines in late 2025 shows regional intent, but still reflects pilot-level penetration rather than broad rollout.

Technology and Practice Trends

One of the clearest trends in the IVL market is the growing use of the technology across both coronary and peripheral workflows rather than in only one procedural niche. This broader procedural footprint is helping strengthen hospital adoption.

Another important trend is the increasing role of IVL in access preparation, especially in large-bore procedures such as TAVR and EVAR. This expands the technology's value beyond lesion preparation alone.

Clinical practice is also moving toward more selective use of premium calcium-modification tools in the most difficult lesions. IVL is benefiting from this trend because it is increasingly viewed as a controlled and vessel-preserving option.

Finally, structured international expansion is becoming more important. The category is moving from a mostly U.S. and Europe-centered business toward broader regional participation, especially in Asia.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

66 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the fastest-growing opportunities in the global IVL market through 2032?

How are coronary and peripheral IVL segments contributing differently to total market expansion?

What role do TAVR, EVAR and complex PCI play in future demand for calcium-modification technologies?

How do premium pricing, reimbursement variability and hospital budget constraints affect adoption across regions?

Which competitors are positioned to shape the market, and how durable is Johnson & Johnson's leadership?

How can suppliers, investors and commercial teams evaluate the long-term opportunity in one of the fastest-growing vascular device categories?

The Global Intravascular Lithotripsy Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, competitive intelligence and forecast modeling. Use it to benchmark category growth, understand procedural demand and support strategy in a rapidly expanding segment of vascular intervention.